ReviewNature2026
Towards intelligent and miniaturized drug delivery devices.
Review in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Controlled Self-Assembly of Gold Nanoparticles for Photo-Enhanced Cancer Imaging and Treatment.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Biointegrated Battery-Based Electroceuticals.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Inflammation-triggered sensing and miRNA immunotherapy with a wireless battery-free hydrogel bioelectronic patch.National science review · 2026Article
- Systematic Design and Evaluation of Nasal Drug Delivery for Central Nervous System Disease from Experimental to Clinical Application.Pharmaceutics · 2026Review
- Fully Automated Biometric Parameter Measurement in Prenatal Ultrasound Screening for Total Anomalous Pulmonary Venous Connection.Bioengineering (Basel, Switzerland) · 2026Article
- Toward autonomous robotic-assisted and microrobotic surgery.Science advances · 2026Review
- Mammary organoid-based depot for post-surgical chemotherapy and gland regeneration.Nature biomedical engineering · 2026Article
- Smart thyroid-regulated drug delivery systems: a review of intelligent biosensor-integrated therapeutics for precision thyroxine replacement.Frontiers in endocrinology · 2026Review
- Soft bioelectronics for wireless drug delivery: programmable, minimally invasive and closed-loop therapeutics.npj soft matter · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Advances at the intersection of biotechnology, artificial intelligence, electronics and materials science are reshaping how drugs can be delivered inside the body. Intelligent and miniaturized drug delivery devices (IMDDDs) leverage these technologies to achieve precise pharmacokinetics, targeted distribution and programmable release while minimizing toxicity and improving patient adherence. Unlike conventional approaches, IMDDDs can incorporate real-time sensing and adaptive control, enabling drug administration that is more precise and more responsive to dynamic physiological conditions. In this Review, we outline key categories and design principles, highlight artificial intelligence technologies for augmenting performance, discuss potential clinical applications across cancer, diabetes, cardiovascular disease, vaccination and beyond, and examine translation challenges and opportunities. By uniting engineering innovation with medical need, IMDDDs exemplify the next generation of drug delivery technologies.
Indexed as
Identifiers
41882132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.